New therapies for inflammatory bowel disease: from the bench to the bedside
New therapies for inflammatory bowel disease: from the bench to the bedside
复制标题
DOI：
10.1136/gutjnl-2011-300904
复制
发表时间：
2012-06-01
期刊：
影响因子：
24.5
通讯作者：
Danese, Silvio
中科院分区：
文献类型：
--
作者：
Danese, Silvio
慢性肠炎是炎症性肠病(IBD)的标志，其潜在的机制是复杂的。病理反应的组成部分包括适应性免疫系统和先天免疫系统，以及肠道上皮和内皮。对这些成分中每一种作用的了解的进步导致了多种生物制剂的开发，这些生物制剂都代表了对难治性克罗恩病或溃疡性结肠炎患者使用现有疗法的替代方案。本研究系统地综述了目前处于临床试验中的新疗法和新兴疗法的作用机制、疗效和安全性，并讨论了IBD治疗的未来方向。
The mechanisms underlying the chronic intestinal inflammation that is a hallmark of inflammatory bowel diseases (IBD) are complex. Components of the pathological response include the adaptive and innate immune systems, as well as the intestinal epithelium and endothelium. Advances in the understanding of the roles of each of these components have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn's disease or ulcerative colitis. This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD.